Market Spotlight: Myelofibrosis (MF)
|出版日期||內容資訊||英文 41 Pages
|市場聚光燈:骨髓纖維化(MF) Market Spotlight: Myelofibrosis (MF)|
|出版日期: 2020年08月14日||內容資訊: 英文 41 Pages|
本報告提供全球骨髓纖維化 (MF) 的治療藥臨床實驗形勢和市場趨勢預測相關分析，疾病概要和流行病學的預測，目前主要治療藥 (已上市/開發中產品) 和臨床實驗的進展，目前未滿足需求和未來的市場機會，臨床實驗/市場將來相關專家的見解等資訊彙整，為您概述為以下內容。
Myelofibrosis is a myeloproliferative neoplasm which can exist as a primary disease known as primary myelofibrosis, or can evolve to post-polycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis from PV or ET. It is characterized by the buildup of scar tissue (fibrosis) in bone marrow, which leads to a reduction in blood cell production.
Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.
Bristol Myers Squibb's Inrebic and Incyte's Jakafi are the only marketed drugs for myelofibrosis. These drugs are administered via the oral route.
The majority of industry-sponsored drugs in active clinical development for myelofibrosis are in Phase II. Therapies in development for myelofibrosis focus on a wide variety of targets. The majority of the pipeline drugs are administered via the oral route.
High-impact upcoming events for drugs in the myelofibrosis space comprise topline Phase III trial results for pacritinib, Reblozyl, momelotinib, and Imetelstat, and an estimated NDA filing for pacritinib.
The overall likelihood of approval of a Phase I hematologic asset is 9.9%, and the average probability a drug advances from Phase III is 61.4%. Drugs, on average, take 9.1 years from Phase I to approval, compared to 9.4 years in the overall oncology space.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for myelofibrosis have been in the early and mid-phases of development, with 86% of trials in Phase I-II, and only 14% in Phase III-IV.
The US has a substantial lead in the number of myelofibrosis clinical trials globally. Germany leads the major European markets, while Israel has the top spot in Asia.
Novartis has the highest number of completed clinical trials for myelofibrosis, with 14 trials.
Novartis leads industry sponsors with the highest overall number of clinical trials for myelofibrosis, followed by Incyte.